Bisphosphonates in metastatic cancer
I think this is a suitable setting to ask a basic question about the
use of bisphosphonates in patients with bone metastases.
Several studies reported an improvement in "skeletal related events" (SRE)
in patients treated with bisphophonates, but I find it quite peculiar that
SRE include not only complications such as fractures, but also further
treatments such as radiotherapy to the bones (see for example the paper by
Rosen et Al. in J Clin Oncol 2003, 21:3150).
Is it correct to consider together a complication of disease and its
Competing interests: No competing interests